Openly accessible

Anti-metastatic and differential effects on protein expression of epigallocatechin-3-gallate in HCCLM6 hepatocellular carcinoma cells

Zhang, Yunjuan, Owusu, Lawrence, Duan, Wei, Jiang, Tao, Zang, Shizhu, Ahmed, Ayaz and Xin, Yi 2013, Anti-metastatic and differential effects on protein expression of epigallocatechin-3-gallate in HCCLM6 hepatocellular carcinoma cells, International journal of molecular medicine, vol. 32, no. 4, pp. 959-964.

Attached Files
Name Description MIMEType Size Downloads
duan-antimetastatic-2013.pdf Published version application/pdf 269.31KB 11

Title Anti-metastatic and differential effects on protein expression of epigallocatechin-3-gallate in HCCLM6 hepatocellular carcinoma cells
Author(s) Zhang, Yunjuan
Owusu, Lawrence
Duan, Wei
Jiang, Tao
Zang, Shizhu
Ahmed, Ayaz
Xin, Yi
Journal name International journal of molecular medicine
Volume number 32
Issue number 4
Start page 959
End page 964
Total pages 6
Publisher Spandidos Publications
Place of publication Athens, Greece
Publication date 2013
ISSN 1107-3756
1791-244X
Keyword(s) 2-dimensional gel electrophoresis
epigallocatechin-3-gallate
hepatocellular carcinoma
metastasis
Summary Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third highest cause of cancer-related mortality in humans. Epigallocatechin-3-gallate (EGCG) has been shown to inhibit the metastatic activity of certain cancer cells. The aim of this study was to determine the effects and molecular mechanism(s) of action of EGCG in human HCC cells. A migration and invasion assay for the metastatic behavior of HCCLM6 cells was performed. The anti-metastatic effects of EGCG were investigated by RT-PCR and gelatin zymography. A total cellular protein profile was obtained using 2-dimensional gel electrophoresis (2-DE), followed by matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF-MS) analyses of proteins with significant differences in expression following treatment with EGCG. The results revealed that EGCG induced apoptosis and inhibited the metastasis of HCCLM6 cells. The anti-metastatic effects of EGCG were associated with the inhibition of matrix metalloproteinase (MMP)-2 and MMP-9 activity. The expression levels of far upstream element (FUSE) binding protein 1 (FUBP1), heat shock protein beta 1 (HSPB1), heat shock 60 kDa protein 1 (chaperonin) (CH60) and nucleophosmin (NPM) proteins, which are associated with metastasis, were significantly altered in the EGCG-treated HCCLM6 cells. The data from the present study suggest that EGCG has potential as a therapeutic agent for the treatment of HCC.
Language eng
Field of Research 111504 Pharmaceutical Sciences
Socio Economic Objective 920102 Cancer and Related Disorders
HERDC Research category C1 Refereed article in a scholarly journal
Copyright notice ©2013, Spandidos Publications
Persistent URL http://hdl.handle.net/10536/DRO/DU:30059555

Document type: Journal Article
Collections: School of Medicine
Open Access Collection
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.

Versions
Version Filter Type
Citation counts: Scopus Citation Count Cited 1 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 21 Abstract Views, 12 File Downloads  -  Detailed Statistics
Created: Thu, 16 Jan 2014, 14:46:19 EST by Jane Moschetti

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.